Drugs / Foralumab

Trials 12 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT05028946 May 2022 → Jul 2023 Crohn disease Tiziana Life Sciences LTD Withdrawn No outcome recorded
Phase 1 NCT05029609 Oct 2021 → Nov 2022 primary progressive multiple sclerosis, secondary progressive multiple sclerosis Tiziana Life Sciences LTD Withdrawn No outcome recorded
Phase 1 NCT06879067 Nov 2018 → Jul 2019 Tiziana Life Sciences LTD Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT00805909 Aug 2007 → Jan 2009 acute transplant rejection Light Chain Bioscience - Novimmune SA Completed No outcome recorded
Phase 1/2 NCT00630643 Jan 2006 → Dec 2007 Crohn disease Light Chain Bioscience - Novimmune SA Completed No outcome recorded
Phase 26 trials
Phase 2 NCT07688239 Jul 2026 → Jul 2027 expected amyotrophic lateral sclerosis Tiziana Life Sciences LTD Not yet recruiting No outcome recorded
Phase 2 NCT06868628 May 2025 → Apr 2027 expected multiple system atrophy Tiziana Life Sciences LTD Recruiting No outcome recorded
Phase 2 NCT06890923 Mar 2025 → Apr 2026 overdue secondary progressive multiple sclerosis Tiziana Life Sciences LTD Recruiting No outcome recorded
Phase 2 NCT06292923 Nov 2023 → Sep 2026 expected secondary progressive multiple sclerosis Tiziana Life Sciences LTD Active not recruiting No outcome recorded
Phase 2 NCT04983446 Apr → Oct 2022 COVID-19 Tiziana Life Sciences LTD Withdrawn No outcome recorded
Phase 2 NCT03291249 Dec 2017 → Dec 2018 metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus Tiziana Life Sciences LTD Withdrawn No outcome recorded
Phase not stated1 trial
NCT06802328 secondary progressive multiple sclerosis Tiziana Life Sciences LTD Available No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06489548 Comparator Sep 2025 → Jun 2026 overdue Alzheimer disease Brigham and Women's Hospital Recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as Foralumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT05028946
10

NCT06890923

NCT07688239

NCT06489548

NCT06292923

NCT06868628

NCT04983446

NCT03291249

NCT06879067

NCT05029609

NCT06802328

Known as NI-0401 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00630643
1

NCT00805909

Known as TZLS-0401 “Foralumab (TZLS-0401) is a fully human IgG1 monoclonal antibody directed against the CD3-epsilon (or CD3ε) antigen expressed on the surface of a type of white blood cell called...” NCT03291249
Known as TZLS-401 “Foralumab TZLS-401 100 µg” NCT06890923
Modality Monoclonal antibody “NI-0401 (anti-CD3 mAB)” NCT00630643
Route Intravenous “daily intravenous NI-0401 treatment” NCT00630643